1. Home
  2. IOVA vs BHVN Comparison

IOVA vs BHVN Comparison

Compare IOVA & BHVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Iovance Biotherapeutics Inc.

IOVA

Iovance Biotherapeutics Inc.

HOLD

Current Price

$2.22

Market Cap

968.6M

Sector

Health Care

ML Signal

HOLD

Logo Biohaven Ltd.

BHVN

Biohaven Ltd.

HOLD

Current Price

$9.61

Market Cap

1.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
IOVA
BHVN
Founded
2007
2013
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
968.6M
1.1B
IPO Year
N/A
2017

Fundamental Metrics

Financial Performance
Metric
IOVA
BHVN
Price
$2.22
$9.61
Analyst Decision
Buy
Buy
Analyst Count
12
16
Target Price
$10.36
$29.79
AVG Volume (30 Days)
16.6M
4.8M
Earning Date
11-06-2025
11-10-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$250,425,000.00
N/A
Revenue This Year
$60.94
N/A
Revenue Next Year
$60.85
$2,219.74
P/E Ratio
N/A
N/A
Revenue Growth
175.62
N/A
52 Week Low
$1.64
$7.48
52 Week High
$9.30
$47.42

Technical Indicators

Market Signals
Indicator
IOVA
BHVN
Relative Strength Index (RSI) 47.43 41.95
Support Level $2.13 $8.29
Resistance Level $2.55 $10.18
Average True Range (ATR) 0.16 0.73
MACD -0.03 0.25
Stochastic Oscillator 25.57 68.83

Price Performance

Historical Comparison
IOVA
BHVN

About IOVA Iovance Biotherapeutics Inc.

Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. its objective is to be the leader in innovating, developing, and delivering tumor-infiltrating lymphocyte, or TIL, therapies for patients with solid tumor cancers.

About BHVN Biohaven Ltd.

Biohaven Ltd is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of life-changing treatments in key therapeutic areas, including immunology, neuroscience, and oncology. Its product pipeline includes Glutamate, Myostatin, Ion channels, Inflammation & Immunology, and Oncology. The company's products target diseases such as neuromuscular and metabolic diseases, antibody-drug conjugates for cancer, obsessive-compulsive disorder, and others.

Share on Social Networks: